Year: 2020

  • Exercise of Options

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 2,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £100,000. New Ordinary Shares and Admission The New Ordinary Shares…

  • Exercise of Options

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 1,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £50,000. New Ordinary Shares and Admission The New Ordinary Shares…

  • Lanstead Capital TR1

    TR-1: Standard form for notification of major holdings To download click here

  • Total Voting Rights

    ImmuPharma plc (“ImmuPharma” or “the Company”), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM. Consequently, the Company’s issued share capital…

  • Result of Broker Option / PDMR Dealings

    ImmuPharma plc (“ImmuPharma” or “the Company”), announces that it has raised £0.95 million (before expenses) pursuant to a Broker Option following the announcement made on 3 August 2022. Under the terms of a placing agreement entered into by the Company with Stanford Capital Partners Limited (“SCP”) and SPARK Advisory Partners Limited on 3 August, the…

  • INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022

    ImmuPharma is pleased to announce that Tim McCarthy, CEO and Tim Franklin, COO, will provide a live investor presentation via the Investor Meet Company platform today, 4 August 2022 at 12:00pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until…

  • Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m

    Related Party Transactions ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a subscription and a placing to raise c£1.1 million (the “Subscription” and “Placing”) through the issue of 21,818,182 new ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at a price of 5 pence…

  • Initiation of research

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes that its joint broker, Stanford Capital Partners (“SCP”) has today initiated research coverage on the Company. The full text of the report can be accessed via SCP’s website: www.stanfordcp.co.uk/research/ and via Research Tree. Investors are required to self-certify and register in order to access…

  • 2022 Result of ANNUAL GENERAL MEETING – all resolutions passed

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. ImmuPharma’s Chairman & CEO, Tim McCarthy said: “We are delighted to have had such overwhelming support from right across…

  • Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that, having met all the Food and Drug Administration’s (“FDA”) requirements, Avion Pharmaceuticals (“Avion”), its US partner, has confirmed that it has sought final regulatory guidance from the FDA, as it actively prepares for the start of the international Phase 3…